Cytochrome P450 3A Inhibitor [EPC]

60444 reported adverse events

Drugs of this class: RITONAVIR LOPINAVIR AND RITONAVIR DARUNAVIR ETHANOLATE AND COBICISTAT ATAZANAVIR AND COBICISTAT COBICISTAT DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE RITONAVIR 100 MG

These side effects are most commonly reported by patients taking drugs of the Cytochrome P450 3A Inhibitor [EPC] class:

# Side effect Count
0 BONE DENSITY DECREASED 8565
1 CHRONIC KIDNEY DISEASE 5468
2 RENAL FAILURE 4954
3 RENAL INJURY 4760
4 PAIN 4694
5 OSTEONECROSIS 4580
6 DRUG INTERACTION 4451
7 ANXIETY 4374
8 TOOTH LOSS 4351
9 BONE LOSS 4304
See all common reactions for Cytochrome P450 3A Inhibitor [EPC]

Drugs of the Cytochrome P450 3A Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 TOOTH INJURY 1999 0.4600
1 BONE DEMINERALISATION 482 0.4551
2 SKELETAL INJURY 4202 0.4059
3 LIPODYSTROPHY ACQUIRED 653 0.3073
4 MITOCHONDRIAL TOXICITY 248 0.3021
5 BONE LOSS 4304 0.2860
6 BONE DENSITY DECREASED 8565 0.2731
7 IMMUNE RECONSTITUTION SYNDROME 333 0.2579
8 CUSHING'S SYNDROME 172 0.2475
9 MULTIPLE FRACTURES 3909 0.2377
See all enriched reactions for Cytochrome P450 3A Inhibitor [EPC]